Reviewing Treatment Decisions for a 66-Year-Old Man With RRMM

Opinion
Video

Dr Fonseca discusses the prognosis of a patient with relapsed/refractory multiple myeloma, noting the patient's history with treatments like venetoclax and dexamethasone, and the ultimate decision to switch to talquetamab, a GPRC5D-directed bispecific antibody.

Related Videos
Related Content